Sarpogrelate Versus Aspirin in Secondary Prevention of Cerebral Infarction: Differential Efficacy in Diabetes? | Zendy

Yukito Shinohara | Zendy; K Nishimaru | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sarpogrelate Versus Aspirin in Secondary Prevention of Cerebral Infarction: Differential Efficacy in Diabetes?

Author(s) -

Yukito Shinohara,

K Nishimaru

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.554246

Subject(s) - medicine , aspirin , hazard ratio , post hoc analysis , confidence interval , cerebral infarction , diabetes mellitus , infarction , subgroup analysis , myocardial infarction , ischemia , endocrinology

The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported. But S-ACCESS failed to demonstrate noninferiority of sarpogrelate to aspirin for preventing the recurrence of cerebral infarction. Here we compare the characteristics of sarpogrelate and aspirin in various subgroups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research